TX-MARY-KAY
12.1.2023 22:22:41 CET | Business Wire | Press release
Throughout 2022, iconic beauty brand Mary Kay—along with its company-sponsored foundations—gave more than 3 million dollars to support women’s causes around the world.
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20230112005756/en/
Female entrepreneurs in Chuxiong, Yunnan Province increased their income and helped preserve the Yunnan Embroidery cultural industry thanks to Mary Kay Women’s Entrepreneurship Program. (Photo: Mary Kay Inc.)
When Mary Kay Ash, legendary businesswoman and philanthropist, opened her business in 1963, she dreamed of empowering women internationally through entrepreneurship, innovation, hard work, and giving back. Nearly 60 years later, Mary Kay employees, Independent Beauty Consultants, and members of the global community keep her dream alive through generous contributions to four company-sponsored foundations delivering impactful support to women and their families in need.
The full foundation reports can be viewed here. Here’s what they were up to in 2022:
Cancers Affecting Women
- In the U.S., the Mary Kay Ash Foundation (MKAF) funded 37 cancer researchers conducting groundbreaking research against cancers affecting women.
- 43% of MKAF cancer research projects are led by women; 100% of clinical trials are women-led.
- MKAF funded nearly $1.7 million in grants for cancers affecting women.
Gender-based Violence
- MKAF funded nearly $1.4 million in grants supporting services for women survivors of domestic violence.
- MKAF supported 4 local domestic violence shelters in North Texas providing women seeking help with vital resources and safety.
- In collaboration with Mary Kay, MKAF supported global partners committed to end violence against women and girls, including CARE and UN Trust Fund. Together, MKAF partners completed over 550 projects around the world.
- Instituto Mary Kay and Mary Kay Brazil received the Silver Award for the Red Cross Campaign “Campanha Sinal Vermelho Contra a Violência Doméstica” at ABEVD Associação Brasileira das Empresas de Venda Direta (Brazil DSA) Anual Congress.
- In Canada, the Mary Kay Ash Charitable Foundation awarded $10,000 each to 16 domestic violence shelters across Canada, totaling $160,000.
Women and Their Families
Mary Kay China and its company-sponsored programs and fund have provided support through the following efforts:
-
Mary Kay Women’s Entrepreneurship Program
-
In cooperation with China Women’s Development Foundation, interest-free revolving loans were provided to four women entrepreneur initiatives in the provinces of Heilongjiang, Ningxia, and Jilin. The initiatives directly benefited 133 women by increasing their annual per capita income by RMB 20,000 yuan.
-
In cooperation with China Women’s Development Foundation, interest-free revolving loans were provided to four women entrepreneur initiatives in the provinces of Heilongjiang, Ningxia, and Jilin. The initiatives directly benefited 133 women by increasing their annual per capita income by RMB 20,000 yuan.
-
Young Women’s Future Fund
-
In cooperation with Adream Foundation, the Young Women’s Future Fund remaining balance will be used to build four Mary Kay Dream Classrooms in Jiangxi to enhance girls’ literacy education.
-
In cooperation with Adream Foundation, the Young Women’s Future Fund remaining balance will be used to build four Mary Kay Dream Classrooms in Jiangxi to enhance girls’ literacy education.
-
Mary Kay China Charity Program
- Since March 2022, the Mary Kay China Charity Program has allocated 1,049,800 yuan to provide protective materials and living supplies to 73 communities in 15 cities as a result of the COVID-19 epidemic.
- Thanks to the joint efforts of Mary Kay China and its Beauty Consultants, the "Smile 1000" project raised funds for 112 cleft-lip repair surgeries in 2022. To date, Mary Kay China has raised funds for 991 surgeries and is on track to achieve the goal of 1,000 smiles in 2023.
- By May, 1,391 Beauty Consultant volunteers had delivered 331 beauty lessons to 9,147 women.
About Mary Kay
One of the original glass ceiling breakers, Mary Kay Ash founded her dream beauty company in 1963 with one goal: enriching women’s lives. That dream has blossomed into a multibillion-dollar company with millions of independent sales force members in nearly 40 countries. As an entrepreneurship development company, Mary Kay is committed to empowering women on their journey to economic independence through education, mentorship, advocacy, networking, and innovation. Mary Kay is dedicated to investing in the science behind beauty and manufacturing cutting-edge skincare, color cosmetics, nutritional supplements, and fragrances. Mary Kay believes in enriching lives today for a sustainable tomorrow, partnering with organizations from around the world focusing on promoting business excellence, supporting cancer research, advancing gender equality, protecting survivors from domestic abuse, beautifying our communities, and encouraging children to follow their dreams. Learn more at marykayglobal.com, find us on Facebook, Instagram, and LinkedIn or follow us on Twitter.
To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.
View source version on businesswire.com: https://www.businesswire.com/news/home/20230112005756/en/
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Galderma Receives U.S. FDA Approval for Differin® Epiduo® Acne Gel Prescription-to-OTC Switch22.5.2026 18:25:00 CEST | Press release
A unique Prescription-to-OTC switch in acne care, this approval expands access to a dermatologist-trusted, prescription-strength treatment for millions of acne sufferers ages 12 years and older Backed by more than 15 years of real-world dermatologist use and a robust clinical research program, this milestone demonstrates the depth of science behind the Differin® and Epiduo® heritage Adapalene plus benzoyl peroxide (0.1/2.5%) was the first FDA-approved, stable, fixed- dose prescription acne treatment to combine of benzoyl peroxide with a retinoid, and is now available over-the-counter The formulation is engineered to target multiple causes of acne more effectively than either of its individual active ingredients alone Galderma (SIX: GALD), the pure-play dermatology category leader, today announced that the United States (U.S.) Food and Drug Administration (FDA) has approved Differin® Epiduo® Acne Gel (Adapalene 0.1% and Benzoyl Peroxide 2.5% Acne Treatment) for over-the-counter (OTC) us
Avanzanite Bioscience’s Partner Agios Announces PYRUKYND® (mitapivat) Approval in the European Union for Adults with Thalassaemia22.5.2026 16:18:00 CEST | Press release
Avanzanite will commercialise and distribute PYRUKYND in Europe under its exclusive agreement with Agios Avanzanite is committed to collaborating with local authorities in the EU to enable access to PYRUKYND for adult patients with thalassaemia Avanzanite Bioscience B.V., a rapidly growing commercial-stage European specialty pharmaceutical company focused on rare diseases, today reported that its partner, Agios Pharmaceuticals, Inc. (Nasdaq: AGIO), a commercial-stage biopharmaceutical company headquartered in Cambridge, Massachusetts focused on delivering innovative medicines for patients with rare diseases, announced that the European Commission has granted marketing authorisation for PYRUKYND® (mitapivat), an oral pyruvate kinase (PK) activator, in adults for the treatment of anaemia associated with transfusion-dependent and non-transfusion-dependent alpha- or beta-thalassaemia, with an orphan medicinal product designation. This press release features multimedia. View the full releas
ICE Brent and ICE WTI Perpetual Futures to Launch on OKX22.5.2026 14:30:00 CEST | Press release
OKX, a blockchain technology and trading company serving more than 120 million customers globally,and Intercontinental Exchange (NYSE: ICE), one of the world's leading providers of financial market technology and data powering global capital markets including the New York Stock Exchange, today announced plans for OKX to launch perpetual futures based on ICE's Brent Crude and WTI Crude energy benchmarks. The products are expected to be available to trade on OKX’s platform in jurisdictions where OKX is licensed to offer perpetual futures products. The new OKX contracts represent a major step forward in expanding regulated access to global commodity markets through digital asset infrastructure. This first product collaboration between OKX and ICE comes after the companies established a strategic relationship in March 2026. ICE operates some of the world’s leading exchanges, clearing houses and market data services across energy, commodities, fixed income and equities markets. ICE’s future
Enhertu® Recommended for Approval in the EU by CHMP for Patients with Previously Treated HER2 Positive Metastatic Solid Tumors22.5.2026 14:00:00 CEST | Press release
Enhertu® (trastuzumab deruxtecan) has been recommended for approval in the European Union (EU) as a monotherapy for the treatment of adult patients with unresectable or metastatic HER2 positive (immunohistochemistry [IHC] 3+) solid tumors who have received prior treatment and who have no satisfactory treatment options. Enhertu is a specifically engineered HER2 directed DXd antibody drug conjugate (ADC) discovered by Daiichi Sankyo (TSE: 4568) and being jointly developed and commercialized by Daiichi Sankyo and AstraZeneca (LSE/STO/NYSE: AZN). The Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) based its positive opinion on results from patients with HER2 positive (IHC 3+) tumors in three phase 2 trials including DESTINY-PanTumor02,DESTINY-Lung01 andDESTINY-CRC02 where Enhertu demonstrated clinically meaningful responses across a broad range of tumors. The recommendation will now be reviewed by the European Commission, which has the authority
Future Health Challenge Awards USD 300,000 to Early Detection and Population Health Sensing Tools on Sidelines of World Health Assembly22.5.2026 13:45:00 CEST | Press release
Global teams recognised in the Future Health Challenge for solutions designed to detect health risks earlier and support faster health system decisions Future Health – A Global Initiative by Abu Dhabi and MIT Solve announce the winners of the inaugural Future Health ChallengeWinning solution equips frontline health workers in low-resource settings with mobile clinical decision-support tools, enabling earlier detection and more effective care deliveryTeams competed for a USD 200,000 grand prize and two USD 50,000 runner-up awards on the sidelines of the 79th World Health Assembly in GenevaWinners recognised for solutions advancing anticipatory, data-driven health systems Three global teams developing early detection and real-time population health monitoring solutions have secured a total of USD 300,000 on the sidelines of the 79th World Health Assembly. The winning solutions address critical challenges in early detection, continuous population insight and more timely decision making, s
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom
